Cost-effectiveness (CE) analysis of pembrolizumab as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States (US).

被引：0
|
作者：
Ramakrishnan, Karthik
Jain, Disha
Gandhi, Jyotika
Chirovsky, Diana Romana
Borse, Rebekah
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] CHEORS, N Wales, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e18013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18013
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States
    Monk, Bradley J.
    van Mens, Sophie
    Hale, Oliver
    Boer, Jennifer
    van Hees, Frank
    Swami, Shilpi
    Muston, Dominic
    Tekin, Cumhur
    Keefe, Steve
    Monberg, Matthew
    ONCOLOGY AND THERAPY, 2025, 13 (01) : 85 - 98
  • [22] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR FIRST-LINE TREATMENT IN PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN THE UNITED STATES
    Monk, Bradley
    Boer, Jennifer
    Van Hees, Frank
    Van Mens, Sophie
    Swami, Shilpi
    Muston, Dominic
    Tekin, Cumhur
    Keefe, Steve
    Monberg, Matthew
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A38 - A38
  • [23] Phase III KEYNOTE-048 study of first-line (1L) pembrolizumab (P) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Asia vs non-Asia subgroup (subgrp) analysis
    Tahara, M.
    Hong, R-L.
    Ishak, W. Z. Wan
    Yen, C-J.
    Sriuranpong, V.
    Takahashi, S.
    Srimuninnimit, V.
    Yeh, S-P.
    Oridate, N.
    Yang, M-H.
    Tanaka, K.
    Nohata, N.
    Koh, Y.
    Roy, A.
    Gumuscu, B.
    Swaby, R. F.
    Ngamphaiboon, N.
    ANNALS OF ONCOLOGY, 2019, 30 : 461 - 461
  • [24] Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC)
    Chen, X.
    Hu, M.
    Jin, T.
    Teng, K.
    Han, Y.
    Zhou, Y.
    Yang, K.
    Zhang, Z.
    Wang, J.
    Cheng, Y.
    Li, W.
    Wang, Z. M.
    Li, B.
    Xia, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S626 - S627
  • [25] PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the US
    Hanna, Glenn J.
    Zheng, Dandan
    Gao, Wei
    Hair, Gleicy M.
    Ai, Lei
    Song, Yan
    Lerman, Nati
    Bidadi, Behzad
    Zion, Abigail
    Zou, Lin
    Tang, Yuexin
    Wang, Liya
    Merchant, Sanjay
    Black, Christopher M.
    ORAL ONCOLOGY, 2025, 161
  • [26] Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States
    Haddad, Robert
    Cohen, Ezra E. W.
    Venkatachalam, Meena
    Young, Kate
    Singh, Prianka
    Shaw, James W.
    Korytowsky, Beata
    Abraham, Pranav
    Harrington, Kevin J.
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 442 - 447
  • [27] Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis
    Burtness, Barbara
    Rischin, Danny
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    de Castro, Gilberto
    Psyrri, Amanda
    Baste, Neus
    Neupane, Prakash
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett G.
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Ishak, Wan Zamaniah Wan
    Ge, Joy
    Swaby, Ramona
    Gumuscu, Burak
    Harrington, Kevin
    CANCER RESEARCH, 2020, 80 (16)
  • [28] Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
    Cirillo, Alessio
    Marinelli, Daniele
    Romeo, Umberto
    Messineo, Daniela
    De Felice, Francesca
    De Vincentiis, Marco
    Valentini, Valentino
    Mezi, Silvia
    Valentini, Filippo
    Vivona, Luca
    Chiavassa, Antonella
    Cerbelli, Bruna
    Santini, Daniele
    Bossi, Paolo
    Polimeni, Antonella
    Marchetti, Paolo
    Botticelli, Andrea
    BMC CANCER, 2024, 24 (01)
  • [29] Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
    Licitra, L.
    Tahara, M.
    Harrington, K.
    Hurtado de Mendoza, M. Olivera
    Guo, Y.
    Aksoy, S.
    Fang, M.
    Zurawski, B.
    Csoszi, T.
    Klochikhin, M.
    de Oliveira, T. B.
    Takahashi, S.
    Yang, M. H.
    Swiecicki, P. L.
    O'Hara, K.
    Shen, J.
    Wang, A.
    Gumuscu, B.
    Benjamin, K.
    Haddad, R. I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E2 - E3
  • [30] Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada
    Sambrook, J.
    Levy, A. R.
    Johnston, K. M.
    Ricard, N. J.
    Bourgault, C.
    Donato, B. M.
    Sheehan, F. G.
    Hotte, S. J.
    Chasen, M. R.
    Briggs, A. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345